50 related articles for article (PubMed ID: 38619111)
1. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
2. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells.
Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R
Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification.
Nassief G; Butt OH; Zhou AY; Ansstas G
JAAD Case Rep; 2024 Jun; 48():59-61. PubMed ID: 38778889
[No Abstract] [Full Text] [Related]
4. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Zhang Y; Huang J; Huang Y; Zhang S; Wu W; Long H; Duan X; Lai Y; Wu W
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179075
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
[TBL] [Abstract][Full Text] [Related]
7. PARP trapping is governed by the PARP inhibitor dissociation rate constant.
Gopal AA; Fernandez B; Delano J; Weissleder R; Dubach JM
Cell Chem Biol; 2024 Jan; ():. PubMed ID: 38262416
[TBL] [Abstract][Full Text] [Related]
8. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
[TBL] [Abstract][Full Text] [Related]
9. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
Fröhlich LM; Villar-Miyar A; Heintze T; Sauer B; Schittek B
Int J Cancer; 2024 Jul; 155(2):203-210. PubMed ID: 38619111
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
11. DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
Nguyen NT; Pacelli A; Nader M; Kossatz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267438
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
